AI assistant
Sending…
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2014
Jul 2, 2014
31580_dirs_2014-07-02_a857d7a9-268d-4692-b0c5-02fa2b4dca8a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2014-07-01
Reporting Person: Higgons John Duncan (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-07-01 | Common stock | S | 12000 | $46.52 | Disposed | 176090 | Direct |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $45.26 to $47.86. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
More from AGIOS PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
Apr 29
Earnings Release
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3